Literature DB >> 6287872

Malignant mesothelioma: ultrastructural distinction from adenocarcinoma.

M J Warhol, W F Hickey, J M Corson.   

Abstract

Mesotheliomas and metastatic adenocarcinomas involving the pleura are frequently difficult to distinguish by light-microscopic and histochemical methods. In a double-blind study, we have compared ultrastructural features of 10 mesotheliomas of epithelial type and 10 adenocarcinomas from the lung, breast, and upper GI tract, i.e., sites known to give rise to metastases which mimic mesothelioma. Mesotheliomas were observed to have a significantly greater microvillus length/diameter ratio (LDR) than adenocarcinomas (p less than 0.01) and more abundant intermediate filaments (p less than 0.001). Mesotheliomas had more complex microvilli than adenocarcinomas, whereas adenocarcinomas had rootlets (2/10 cases) and lamellar inclusion bodies (2/10 cases), both of which were absent in the mesotheliomas. This study provides quantitative and qualitative ultrastructural features of potential utility in the differential diagnosis of pleural mesotheliomas and adenocarcinomas.

Entities:  

Mesh:

Year:  1982        PMID: 6287872

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

Review 1.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.

Authors:  K Sheibani; H Battifora; J S Burke
Journal:  Am J Pathol       Date:  1986-05       Impact factor: 4.307

3.  Molecular characterization of diffuse malignant peritoneal mesothelioma.

Authors:  Yin P Hung; Fei Dong; Matthew Torre; Christopher P Crum; Raphael Bueno; Lucian R Chirieac
Journal:  Mod Pathol       Date:  2020-06-05       Impact factor: 7.842

4.  Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1.

Authors:  M L Warnock; A Stoloff; A Thor
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

5.  Ultrastructural aspects of the histogenesis of diffuse and localized mesothelioma.

Authors:  I Dardick; J R Srigley; W T McCaughey; A W van Nostrand; A C Ritchie
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

6.  The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance.

Authors:  G A Blobel; R Moll; W W Franke; K W Kayser; V E Gould
Journal:  Am J Pathol       Date:  1985-11       Impact factor: 4.307

7.  Demonstration of keratin in human adenocarcinomas.

Authors:  F Ramaekers; J Puts; O Moesker; A Kant; P Jap; P Vooijs
Journal:  Am J Pathol       Date:  1983-05       Impact factor: 4.307

8.  ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.

Authors:  C J O'Hara; J M Corson; G S Pinkus; R A Stahel
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

9.  Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.

Authors:  I Lee; J A Radosevich; G Chejfec; Y X Ma; W H Warren; S T Rosen; V E Gould
Journal:  Am J Pathol       Date:  1986-06       Impact factor: 4.307

Review 10.  Serous effusions: diagnosis of malignancy beyond cytomorphology. An analytic review.

Authors:  S K Mohanty; P Dey
Journal:  Postgrad Med J       Date:  2003-10       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.